Drug Trial Radar · NCT00237939
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
Last checked: Nov 19, 2026Latest source record: Nov 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
Sep 2002
Primary completion
Nov 2006
Study completion Nov 2006
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- Collaborators
- Otsuka America Pharmaceutical
- First posted
- Oct 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.
Conditions
- Schizophrenia
Interventions
AripiprazoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Global Impression-Improvement at endpoint
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Local Institution
Antwerp, Belgium
Local Institution
Brussels, Belgium
Local Institution
Diest, Belgium
Local Institution
Kortenberg, Belgium
Local Institution
Liège, Belgium
Local Institution
Sint-Michiels, Belgium
Local Institution
Sint-Niklaas, Belgium
Local Institution
Sint-Truiden, Belgium
Local Institution
Tournai, Belgium
Local Institution
Rennes, France
Local Institution
Amersfoort, Netherlands
Local Institution
Raalte, Netherlands
Local Institution
Rotterdam, Netherlands
Local Institution
Barcelos, Portugal
Local Institution
Ceira, Portugal
Local Institution
Coimbra, Portugal
Local Institution
Lisbon, Portugal
Local Institution
Barcelona, Spain
Local Institution
Salamanca, Spain
Local Institution
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.